Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases

Folia Biologica

Volumn 55, Issue 1, 2009, Pages 23-26

  Fialová, Lenka ^a   Bartos A ^a,c   Soukupova J ^a   Svarcova J ^a   Ridzon P ^b   Malbohan, I ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Department of Neurology   (Czech Republic)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOSKELETON PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NEUROFILAMENT L PROTEIN; NEUROFILAMENT M PROTEIN; TUBULIN; UNCLASSIFIED DRUG;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNE SYSTEM; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; SHY DRAGER SYNDROME;

EID: 63449087027     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Al-Chalabi, A., Miller, C. C. (2003) Neurofilaments and neurological disease. Bioessays 25, 346-55.
2. Bartos, A., Fialova, L., Soukupova, J., Kukal, J., Malbohan, I., Pitha, J. (2007a) Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 254, 20-25.
3. Bartos, A., Fialova, L., Soukupova, J., Kukal, J., Malbohan, I., Pitha, J. (2007b) Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol. Scand. 116, 100-107.
4. Bornstein, N. M., Aronovich, B., Korczyn, A. D., Shavit, S., Michaelson, D. M., Chapman, J. (2001) Antibodies to brain antigens following stroke. Neurology 56, 529-530.
5. Couratier, P., Yi, F. H., Preud'homme, J. L., Clavelou, P., White, A., Sindou, P., Vallat, J. M., Jauberteau, M. O. (1998) Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 154, 137-145.
6. Ehling, R., Lutterotti, A., Wanschitz, J., Khalil, M., Gneiss, C., Deisenhammer, F., Reindl, M., Berger, T. (2004) Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult. Scler. 10, 601-606.
7. Eikelenboom, M. J., Petzold, A., Lazeron, R. H., Silber, E., Sharief, M., Thompson, E. J., Barkhof, F., Giovannoni, G., Polman, C. H., Uitdehaag, B. M. (2003) Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 60, 219-223.
8. Fabriek, B. O., Zwemmer, J. N., Teunissen, C. E., Dijkstra, C. D., Polman, C. H., Laman, J. D., Castelijns, J. A. (2005) In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J. Neuroimmunol. 161, 190-194.
9. Kurki, P., Helve, T., Dahl, D., Virtanen, I. (1986) Neurofilament antibodies in systemic lupus erythematosus. J. Rheumatol. 13, 69-73.
10. Kurtzke, J. F. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452.
11. Lublin, F. D., Reingold, S. C. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907-911.
12. Petzold, A. (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233, 183-198.
13. Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., Tourtellotte, W. W. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227-231.
14. Prat, A., Antel, J. (2005) Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18, 225-230.
15. Reiber, H., Ungefehr, S., Jacobi, C. (1998) The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler. 4, 111-117.
16. Roxburgh, R. H., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., Edan, G., McDonnell, G. V., Hawkins, S., Trojano, M., Liguori, M., Cocco, E., Marrosu, M. G., Tesser, F., Leone, M. A., Weber, A., Zipp, F., Miterski, B., Epplen, J. T., Oturai, A., Soelberg Sørensen, P., Celius, E. G., Téllez Lara, N., Montalban, X., Villoslada, P., Silva, A. M., Marta, M., Leite, I., Dubois, B., Rubio, J., Butzkueven, H., Kilpatrick, T., Mycko, M. P., Selmaj, K. W., Rio, M. E., Sá, M., Salemi, G., Savettieri, G., Hillert, J., Compston, D. A. S. (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64, 1144-1151.
17. Sadiq, S. A., van den Berg, L. H., Thomas, F. P., Kilidireas, K., Hays, A. P., Latov, N. (1991) Human monoclonal antineurofilament antibody cross-reacts with a neuronal surface protein. J. Neurosci. Res. 29, 319-325.
18. Salih, A. M., Nixon, N. B., Dawes, P. T., Mattey, D. L. (1998) Prevalence of antibodies to neurofilament polypeptides in patients with rheumatoid arthritis complicated by peripheral neuropathy. Clin. Exp. Rheumatol. 16, 689-694.
19. Silber, E., Semra, Y K., Gregson, N. A., Sharief, M. K. (2002) Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 58, 1372-1381.
20. Skoda, D., Kranda, K., Bojar, M., Glosova, L., Baurle, J., Kenney, J., Rompord, D., Pelichovska, M., Cvachovec, K. (2006) Antibody formation against β-tubulin class III in response to brain trauma. Brain Res. Bull. 68, 213-216.
21. Svarcova, J., Fialova, L., Bartos, A., Steinbachova, M., Malbohan, I. (2008) Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. Eur. J. Neurol. 15, 1173-1179.
22. Terryberry, J. W., Thor, G., Peter, J. B. (1998) Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 19, 205-216.
23. Zaffaroni, M. (2003) Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol. Sci. 24 Suppl 5, S279-282.